Theophylline in Dextrose Viaflex
"The U.S. Food and Drug Administration today approved Nucala (mepolizumab) for use with other asthma medicines for the maintenance treatment of asthma in patients age 12 years and older. Nucala is approved for patients who have a history of "...
Theophylline 5% Dextrose Injection Viaflex
THEOPHYLLINE IN DEXTROSE
(theophylline anhydrous) Injection, Solution
USP in Plastic Container
VIAFLEX Plus Container
Theophylline in 5% Dextrose Injection, USP is a sterile, nonpyrogenic solution of Theophylline, Anhydrous, USP in 5% Dextrose Injection. It contains no antimicrobial agents. Theophylline is structurally classified as a methylxanthine. It occurs as a white, odorless, crystalline powder with a bitter taste. Anhydrous theophylline has the chemical name 1H-Purine-2,6-dione,3,7-dihydro-1,3-dimethyl-, and is represented by the following structural formula:
The molecular formula of anhydrous theophylline is C7H8N4O2 with a molecular weight of 180.17. Dextrose Hydrous, USP has the chemical name D-Glucose monohydrate and is represented by the following structural formula:
Theophylline in 5% Dextrose Injection, USP is intended for intravenous administration. Composition, osmolarity, pH and caloric content are shown in Table I.
|Size (mL)||Composition||Osmolarity* (mOsmol/L) (calc)||pH||Caloric Content (kcal/L)|
|Theophylline Anhydrous, USP (mg/container)||Dextrose Hydrous, USP(g/L)|
|200 mg Theophyllinein
5% Dextrose Injection, USP
|50||200||50||275||4.5(3.5 to 6.5)||170|
|100||200||50||263||4.5(3.5 to 6.5)||170|
|400 mg Theophylline in 5% Dextrose Injection, USP||100||400||50||275||4.5 (3.5 to 6.5)||170|
|250||400||50||261||4.5 (3.5 to 6.5)||170|
|500||400||50||257||4.5 (3.5 to 6.5)||170|
|1000||400||50||255||4.5 (3.5 to 6.5)||170|
|800 mg Theophylline in 5% Dextrose Injection, USP||250||800||50||270||4.5 (3.5 to 6.5)||170|
|500||800||50||261||4.5 (3.5 to 6.5)||170|
|1000||800||50||257||4.5 (3.5 to 6.5)||170|
|*Normal physiologic osmolarity range is approximately 280 to 310 mOsmol/L. Administration of substantially hypertonic solutions ( ≥ 600 mOsmol/L) may cause vein damage.|
This VIAFLEX Plus plastic container is fabricated from a specially formulated polyvinyl chloride (PL 146 Plastic). VIAFLEX Plus on the container indicates the presence of a drug additive in a drug vehicle. The VIAFLEX Plus plastic container system utilizes the same container as the VIAFLEX plastic container system. The amount of water that can permeate from inside the container into the overwrap is insufficient to affect the solution significantly. Solutions in contact with the plastic container can leach out certain of its chemical components in very small amounts within the expiration period, e.g., di-2-ethylhexyl phthalate (DEHP), up to 5 parts per million. However, the safety of the plastic has been confirmed in tests in animals according to USP biological tests for plastic containers as well as by tissue culture toxicity studies.
Last reviewed on RxList: 2/10/2009
This monograph has been modified to include the generic and brand name in many instances.
Additional Theophylline 5% Dextrose Injection Viaflex Information
Report Problems to the Food and Drug Administration
You are encouraged to report negative side effects of prescription drugs to the FDA. Visit the FDA MedWatch website or call 1-800-FDA-1088.
Allergies & Asthma
Improve treatments & prevent attacks.